Savient Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Savient Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Savient Pharmaceuticals: 5 sponsored US clinical trials, none currently recruiting.
Savient Pharmaceuticals sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 3 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gout, with 2 trials.
Upper-quartile sponsor footprint
Savient Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
NCT01739660
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
NCT00675103
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
NCT01356498
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
NCT00325195
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
NCT00080210
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Therapeutic Areas
How the Savient Pharmaceuticals archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 3 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Gout (2 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Savient Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Savient Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Savient Pharmaceuticals page
5 registered trials is a research-attention snapshot, not an endorsement of Savient Pharmaceuticals or any single study.
- None of Savient Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Gout is the condition Savient Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gout trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Savient Pharmaceuticals pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.